Great Novel Therapeutics Biotech & Medicals

TWO:7427 Taiwan Biotechnology

Market Cap

$42.43 Million

NT$1.40 Billion TWD

Market Cap Rank

#23024 Global

#1350 in Taiwan

Share Price

NT$31.40

Change (1 day)

-1.10%

52-Week Range

NT$30.40 - NT$55.80

All Time High

NT$55.80

Great Novel Therapeutics Biotech & Medicals - Asset Resilience Ratio

Latest as of June 2025: 53.31%

Great Novel Therapeutics Biotech & Medicals (7427) has an Asset Resilience Ratio of 53.31% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$313.00 Million

Cash + Short-term Investments

Total Assets

NT$587.17 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Great Novel Therapeutics Biotech & Medicals's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Great Novel Therapeutics Biotech & Medicals's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$313.00 Million	53.31%
Total Liquid Assets	NT$313.00 Million	53.31%

Asset Resilience Insights

Very High Liquidity: Great Novel Therapeutics Biotech & Medicals maintains exceptional liquid asset reserves at 53.31% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.